Funding This work was supported by ongoing institutional funding
This post covers what the Bridge is, who qualifies, how it interacts with Medicares existing GLP-1 coverage for cardiovascular risk reduction, and how it connects to the previously-announced BALANCE Model
Discover how our innovative, vegan Skinosya SAG meets evolving consumer expectations while delivering superior performance
AstraZeneca) in 2017, and semaglutide (Ozempic
Research & Innovation Disclosure STAAR LABS collaborates with clinics, pharmacies, and healthcare professionals to advance innovation in real-world metabolic health protocols
Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications